Information on The Ohio State University Comprehensive Cancer Center (OSUCCC)
The James is a cutting-edge research facility where discovery is translated into more effective prevention and diagnostic strategies as well as more effective and safer treatments. Among recent research advances:
- The James was one of many sites in a national study involving 18,000 men that demonstrated the ability of a hormonal agent, finasteride, to reduce the risk of prostate cancer by 25 percent. More than 250 men in Ohio and Kentucky participated through the Ohio State clinics directed by Steven K. Clinton, MD, PhD, and Robert Bahnson, MD. The study was the first in history to demonstrate that an intervention could protect men from developing prostate cancer.
- The James is participating in the largest prostate cancer prevention trial to date, called SELECT (Selenium and Vitamin E Cancer Prevention Trial). The Ohio State effort, directed by J. Paul Monk, MD, and Drs. Clinton and Bahnson, will determine whether dietary supplements of vitamin E and selenium can prevent prostate cancer. The 12-year study is expected to involve more than 400 trial sites, with approximately 32,000 healthy men over the age of 55 (over 50 for African-Americans) participating.
- Dr. Clinton and colleagues at the OSUCCC – James are seeking to prove whether consumption of tomato-based products and soy can reduce the risk of prostate cancer, as epidemiologic studies have suggested. These investigators are bringing dietary and nutritional studies into the clinic, where men with prostate cancer are able to participate in these important and exciting clinical trials
Find a doctor
*Source: National Cancer Institute; The Ohio State University Comprehensive Cancer Center (OSUCCC)